Combining MRD with genetic knowledge in ALL
Measurable residual disease (MRD) is arguably the most useful single prognostic tool we have within the field of acute lymphoblastic leukemia (ALL), discusses Anthony Moorman, PhD, of Newcastle Univer... Author: VJHemOnc Added: 07/18/2018
Authors: Seol CA, Cho YU, Jang S, Park CJ, Lee JH, Seo EJ PMID: 31432644 [PubMed - in process]
Leukemia, Published online: 22 August 2019; doi:10.1038/s41375-019-0531-8New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models
The role of hematopoietic cell transplantation (HCT) for adults with acute lymphoblastic leukemia (ALL) is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the recommendations. A panel of ALL experts developed consensus on the treatment recommendations based upon the evidence. Allogeneic HCT offers a survival benefit in selected patients with ALL and this review summarizes the standard indications as well as the areas of controversy.
toro Donato Gemmati Childhood acute lymphoblastic leukemia (ALL) peaks around age 2–4, and in utero genetic epigenetic mother-fetus crosstalk might tune ALL onset during childhood life. Folate genes variably interact with vitamin status on ALL risk and prognosis. We investigated DHFR and MTHFR gene variants in 235 ALL children and their mothers to disclose their role in determining ALL onset age and survival. Pyrosequence of DHFR 19bp ins/del (rs70991108; W/D), MTHFR C677T (rs1801133; C>T), and MTHFR A1298C (rs1801131; A>C) was assessed in children and in 72% of mothers for dyad-analysis compa...
Germ line mutations in ETV6 are responsible for a familial thrombocytopenia and leukemia predisposition syndrome. Thrombocytopenia is almost completely penetrant and is usually mild. Leukemia is reported in ~30% of carriers and is most often B-cell acute lymphoblastic leukemia. The mechanisms by which ETV6 dysfunction promotes thrombocytopenia and leukemia remain unclear. Care for individuals with ETV6-related thrombocytopenia and leukemia predisposition includes genetic counseling, treatment or prevention of excessive bleeding and surveillance for the development of hematologic malignancy.
We present an adult with a hematologic malignancy who developed extensive eruptive XG. A 59-year-old Caucasian male with active B-cell acute lymphoblastic leukemia (B-ALL) developed numerous nonpruritic, nonpainful lesions over the course of three weeks after receiving multiple rounds of chemotherapy. Physical exam revealed innumerable pink to yellow 1-5 mm firm glossy papules on the right neck, chest, abdomen, and back.
A 15-year old male with pre-B cell acute lymphoblastic leukemia was admitted for presumed septic shock secondary to an unknown infectious etiology. Thepatient was started on broad spectrum IV antibiotic therapy and bloodcultures were obtained at admission. On the second day of hospitalization,the patient developed approximately 10-15 discrete 3-6 mm pink to violaceouspapules scattered on his chest and proximal upper extremities. Over the course of 2-3 hours these increased in number to over 50 lesions with involvement of distal extremities.
Case Report: A 63-year-old man had been diagnosed of chronic myelomonocytic leukemia on 2015 which was asymptomatic and not treated. On 2017, he presented abruptly with skin lesions that looked like bruises but were infiltrated and affected the face and upper back. Cutaneous and bone marrow biopsy ruled out leukemia cutis and it was diagnosed of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Therefore he started chemotherapy using the protocol for acute lymphoblastic leukemia ALL OLD>55 years.
Authors: Petrou P Abstract Introduction: The new category of chimeric antigen receptor T - cell raised hopes for a more effective treatment of large B cell lymphoma and acute lymphoblastic leukemia. Nevertheless, their soaring acquisition costs will stretch the fiscal capacity of the health systems worldwide. To this direction, the scope of this study is to provide a systematic review of their economic evaluations. Areas covered: A systematic review of the economic evaluations of tisagenlecleucel and axicabtagene was performed. Expert opinion: The available data indicate that these products demonstrate a potentiall...